ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC
- 1 August 1999
- journal article
- clinical trial
- Published by Elsevier BV in Radiotherapy and Oncology
- Vol. 52 (2), 149-156
- https://doi.org/10.1016/s0167-8140(99)00106-1
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of CancerRadiotherapy and Oncology, 1998
- Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 1997
- Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and complianceRadiotherapy and Oncology, 1997
- ARCON—Current Status: Summary of a Workshop on Preclinical and Clinical StudiesActa Oncologica, 1997
- 75 Dependence of radiosensitisation on irradiating at the time of peak nicotinamide tumour concentrationRadiotherapy and Oncology, 1996
- A convenient and reliable method for carbogen breathing in manRadiotherapy and Oncology, 1993
- Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerationsBritish Journal of Cancer, 1993
- Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC)Radiotherapy and Oncology, 1993
- Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapyRadiotherapy and Oncology, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958